Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylstilbestrol Diphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.55 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylstilbestrol Diphosphate SCHEMBL6231203 | 1.00 | BLM (1.00) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL2496868 | 0.98 | BLM (0.96) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL809597 | 0.98 | BLM (0.96) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL3664191 | 0.96 | BLM (0.93) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL707840 | 0.93 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL707841 | 0.93 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL7617243 | 0.93 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL14608595 | 0.90 | BLM (0.81) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL5488347 | 0.86 | BLM (0.74) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL8937910 | 0.85 | BLM (0.72) | BLMNR1I2SMN1; SMN2ESR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8185 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735116-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4282490-B1 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY | ETH ZUERICH (CH) | 2025-11-12 | — | — | EP | claimed |
| CN-119907692-A | Isolated targeted delivery system for the treatment of gliomas | 塞尔丽思股份公司 | 2025-04-29 | — | — | CN | claimed |
| WO-2025080751-A2 | ANTI-CDH17 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-20250075182-A1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2025-03-06 | — | — | US | claimed |
| CN-119505441-A | High impact resistance HPVC power tube and processing technology thereof | 杭州百诺电力科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| WO-2025006846-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-01-02 | — | — | WO | claimed |
| CN-118302433-A | Fibronectin binding peptides for diagnosis and treatment of tumors or fibrosis | 苏黎世联邦理工学院 | 2024-07-05 | — | — | CN | claimed |
| EP-1121366-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 2001-08-08 | — | — | EP | claimed |
| EP-1083896-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2001-03-21 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000074684-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING POSTMENOPAUSAL AND PERIMENOPAUSAL WOMEN, AND THEIR USE | THE GENERAL HOSPITAL CORPORATION (US) | 2000-12-14 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999058126-B1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | ENDOWMENT RES INHUMAN BIOLOGY (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999058126-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| WO-1999051613-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 1999-10-14 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0392745-B1 | Immunoconjugates and prodrugs and their use in association for drug delivery | CELLTECH LTD (GB) | 1994-11-02 | — | — | EP | claimed |